Andelyn Biosciences partnered with South Korea-based ENCell to build a dual-hemisphere manufacturing bridge aimed at accelerating global delivery of cell and gene therapies. The collaboration is positioned to connect U.S. and APAC manufacturing hubs using both companies’ GMP capabilities and regional clinical networks. Under the agreement, Andelyn and ENCell plan to streamline development and manufacturing for client programs, including support for in-country manufacturing tied to in-country clinical trials. That structure is designed to reduce lead times and logistical delays involved in expanding gene-therapy manufacturing capacity across regions. The deal reflects continuing pressure on CGT developers to scale while meeting regional regulatory and supply-chain requirements. For sponsors, the manufacturing bridge model can reduce time-to-execution when clinical trial sites and patient populations are distributed internationally. The partnership also underscores how CDMOs are competing on operational throughput and regulatory readiness as much as on bench-to-GMP translation.